NEURONAX obtains the authorization to start its phase I clinical trial in France and Belgium and strengthens its patent portfolio

Saint-Beauzire, Lyon, February 28, 2017, NEURONAX, the biopharmaceutical company specialized in neuronal regeneration, has been authorized to start its Phase I clinical trial by the Healthcare Authorities (French National Agency for Medicines and Health Products Safety (ANSM) for France and The Federal Agency for Medicines and Health Products (FAMHP) for … Read more

NEURONAX supports IRME

In coherence with its vocation , Neuronax supports the Institute for Research on Spinal Cord and Encephalon (IRME). The mission of … Read more

NEURONAX at Bio-Europe 2016

NEURONAX is present in Biotechnology partnering Conference Bio-Europe in Cologne, 7-9 November 2016. NEURONAX’s CEO, Dr. Yann Godfrin and Founder … Read more